1. Academic Validation
  2. Structure-Activity Relationships of Withanolides as Antiproliferative Agents for Multiple Myeloma: Comparison of Activity in 2D Models and a 3D Coculture Model

Structure-Activity Relationships of Withanolides as Antiproliferative Agents for Multiple Myeloma: Comparison of Activity in 2D Models and a 3D Coculture Model

  • J Nat Prod. 2021 Aug 27;84(8):2321-2335. doi: 10.1021/acs.jnatprod.1c00446.
Micaela F Freitas Misakyan 1 2 3 E M Kithsiri Wijeratne 4 Mark E Issa 1 2 3 Ya-Ming Xu 4 Aymeric Monteillier 1 2 3 A A Leslie Gunatilaka 4 Muriel Cuendet 1 2 3
Affiliations

Affiliations

  • 1 School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland.
  • 2 Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland.
  • 3 Translational Research Centre in Oncohaematology, 1211 Geneva, Switzerland.
  • 4 Southwest Center for Natural Products Research, School of Natural Resources and the Environment, College of Agriculture and Life Sciences, The University of Arizona, Tucson, Arizona 85706, United States.
Abstract

Multiple myeloma (MM) is a hematological Cancer in which relapse and resistance are highly frequent. Therefore, alternatives to conventional treatments are necessary. Withaferin A, a withanolide isolated from Withania somnifera, has previously shown promising activity against various MM models. In the present study, structure-activity relationships (SARs) were evaluated using 56 withanolides. The antiproliferative activity was assessed in three MM cell lines and in a 3D MM coculture model to understand the in vitro activity of compounds in models of various complexity. While the results obtained in 2D allowed a quick and simple evaluation of cytotoxicity used for a first selection, the use of the 3D MM coculture model allowed filtering compounds that perform better in a more complex setup. This study shows the importance of the last model as a bridge between 2D and in vivo studies to select the most active compounds and ultimately lead to a reduction of animal use for more sustained in vivo studies. NF-κB inhibition was determined to evaluate if this could be one of the targeted pathways. The most active compounds, withanolide D (2) and 38, should be further evaluated in vivo.

Figures
Products